BIOMAT Database Logo BIOMAT Database Logo

KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate. 2021

Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Team Resist, UMR1184, Immunology of Viral, Auto-Immune, Hematological, and Bacterial Diseases, INSERM, Université Paris-Saclay, CEA, LabEx LERMIT, Faculty of Medicine, Le Kremlin-Bicêtre, France.

Resistance to the ceftazidime (CAZ)-avibactam (AVI) combination is increasingly being reported. Here, we report a CAZ-AVI-resistant Klebsiella pneumoniae strain belonging to the high-risk sequence type 307 (ST307) clone and producing Klebsiella pneumoniae carbapenemase 39 (KPC-39), a single-amino-acid variant of KPC-3 (A172T). Cloning experiments, steady-state kinetic parameters, and molecular dynamics simulations revealed a loss of carbapenemase activity and increased affinity for CAZ. KPC-39 was identified in a patient without prior exposure to CAZ-AVI, suggesting silent dissemination in European health care settings.

UI MeSH Term Description Entries
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes

Related Publications

Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.
August 2021, Antimicrobial agents and chemotherapy,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
October 2015, Antimicrobial agents and chemotherapy,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
June 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Molecular Mechanisms Responsible KPC-135-Mediated Resistance to Ceftazidime-Avibactam in ST11-K47 Hypervirulent Klebsiella pneumoniae.
May 2024, Emerging microbes & infections,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella pneumoniae.
December 2021, Emerging microbes & infections,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study.
April 2023, Antibiotics (Basel, Switzerland),
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
November 2019, The Journal of antimicrobial chemotherapy,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Genomic characterisation of a novel KPC-98-producing clinical Klebsiella pneumoniae strain conferring resistance to ceftazidime/avibactam.
December 2023, International journal of antimicrobial agents,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 Klebsiella pneumoniae clinical strain.
September 2023, Microbiology spectrum,
Agnès B Jousset, and Saoussen Oueslati, and Cécile Emeraud, and Rémy A Bonnin, and Laurent Dortet, and Bogdan I Iorga, and Thierry Naas
A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
March 2024, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
Copied contents to your clipboard!